Issue 4/2021
Content (11 Articles)
Risk and Benefit for Targeted Therapy Agents in Pediatric Phase II Trials in Oncology: A Systematic Review with a Meta-Analysis
Karolina Strzebonska, Mateusz T. Wasylewski, Lucja Zaborowska, Maciej Polak, Emilia Slugocka, Jakub Stras, Mateusz Blukacz, Bishal Gyawali, Marcin Waligora
Safety and Efficacy of Neoadjuvant Immune Checkpoint Inhibitor Therapy in Patients with Resectable Non-small-Cell Lung Cancer: A Systematic Review
Ziran Zhao, Yibo Gao, Qi Xue, Shugeng Gao, Jie He
Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Esophageal Adenocarcinoma: Results from a Phase 1 Cohort
Benjamin Tan, Adnan Khattak, Enriqueta Felip, Karen Kelly, Patricia Rich, Ding Wang, Christoph Helwig, Isabelle Dussault, Laureen S. Ojalvo, Nicolas Isambert
Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Patients with Esophageal Squamous Cell Carcinoma: Results from a Phase 1 Cohort in Asia
Chia-Chi Lin, Toshihiko Doi, Kei Muro, Ming-Mo Hou, Taito Esaki, Hiroki Hara, Hyun Cheol Chung, Christoph Helwig, Isabelle Dussault, Motonobu Osada, Shunsuke Kondo
Multicenter, Open-Label, Phase I Study of DSP-7888 Dosing Emulsion in Patients with Advanced Malignancies
Alexander Spira, Aaron R. Hansen, Wael A. Harb, Kelly K. Curtis, Erina Koga-Yamakawa, Makoto Origuchi, Zhonggai Li, Bella Ertik, Walid L. Shaib
Cardiovascular Toxicities of Antiangiogenic Tyrosine Kinase Inhibitors: A Retrospective, Pharmacovigilance Study
Adam Goldman, David Bomze, Rachel Dankner, Dana Fourey, Ben Boursi, Michael Arad, Elad Maor
Starting Imatinib at 400 mg Daily in Patients with Gastrointestinal Stromal Tumors Harboring KIT Exon 9 Mutations: A Retrospective, Multicenter Study
Almudena Callejo, Sara Faouzi, Olivier Bouché, François Bertucci, Thomas Chevalier, Nicolas Isambert, Florence Duffaud, Olivier Collard, Nicolas Penel, Philippe Terrier, Olivier Mir, Jean Yves Blay, Axel Le Cesne
Prognostic Impact of Early Treatment Interruption of Nivolumab Plus Ipilimumab Due to Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma: A Multi-Institution Retrospective Study
Hiroki Ishihara, Yuki Nemoto, Kazutaka Nakamura, Takashi Ikeda, Hidekazu Tachibana, Hironori Fukuda, Kazuhiko Yoshida, Hirohito Kobayashi, Junpei Iizuka, Hiroaki Shimmura, Yasunobu Hashimoto, Toshio Takagi, Hideki Ishida, Tsunenori Kondo, Kazunari Tanabe
Baseline and Changes in Serum B-Cell Maturation Antigen Levels Rapidly Indicate Changes in Clinical Status Among Patients with Relapsed/Refractory Multiple Myeloma Starting New Therapy
Sean Bujarski, Kyle Udd, Camilia Soof, Haiming Chen, Tanya M. Spektor, Tahmineh Safaie, Mingjie Li, Joshua Stern, Cathy Wang, Ning Xu, Marsiye Emamy-Sadr, Regina Swift, Ashkon Rahbari, Saurabh Patil, Eric Souther, Bernard Regidor, Christine Sutanto, James R. Berenson
The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment
Pina Ziranu, Eleonora Lai, Marta Schirripa, Marco Puzzoni, Mara Persano, Andrea Pretta, Giada Munari, Nicole Liscia, Valeria Pusceddu, Fotios Loupakis, Laura Demurtas, Michela Libertini, Stefano Mariani, Marco Migliari, Marco Dubois, Riccardo Giampieri, Giovanni Sotgiu, Angelo Paolo Dei Tos, Sara Lonardi, Alberto Zaniboni, Matteo Fassan, Mario Scartozzi
The Pan-Immune-Inflammation Value in Patients with Metastatic Melanoma Receiving First-Line Therapy
Giovanni Fucà, Teresa Beninato, Marta Bini, Laura Mazzeo, Lorenza Di Guardo, Carolina Cimminiello, Giovanni Randon, Giulia Apollonio, Ilaria Bisogno, Marta Del Vecchio, Claudia Lauria Pantano, Massimo Di Nicola, Filippo de Braud, Michele Del Vecchio